undamentalytics Newsletter
Sign in

Sarepta Therapeutics, Inc. (SRPT) stock

Add to watchlist

Add holding +

NASDAQ: SRPT Nasdaq Biotechnology Next results ~November 5, 2026

Sarepta Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Sarepta Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds142 adding, 183 cuttingOf 58 active managers that changed their stake, 31 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Sarepta Therapeutics files

Where Sarepta Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.97bn, down 20.4% on a year earlier, a steeper fall than the 2.2% decline a quarter earlier. Free-cash-flow margin rose to 4.1% from -18.2% a year earlier. Operating margin narrowed to -7.3% from -0.0%. The diluted share count is down 3.1% on a year earlier, which lifts each remaining share. It passes 3 of our 7 financial-health checks.

Our model value for Sarepta Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Sarepta Therapeutics, Inc.'s trailing-twelve-month revenue fell 20.4% year on year, with a free-cash-flow margin of 4.1%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -20.4% (-18.2pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 3.1% in a year, so each share owns more of the business.

Things to watch

  • Revenue shrinking. Revenue fell 20.4% over the last 12 months.
  • Growth slowing. The growth rate is 18.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -7.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 7.2 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 79% and a beta of 2.1 against the S&P 500.
  • Gross margin slipping. Gross margin is down 30.6 points on a year ago.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.64 against an average estimate of $0.49: beat by 31.7%
Revenue
$401m, down 34.3% on a year earlier
Share reaction
+2.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 5, 2026; average EPS estimate $0.36

Sarepta Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.6%
  • 1 week+1.9%
  • 1 month+4.7%
  • This year-14.9%
  • 1 year-23.7%
  • 5 years-78.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2B
Operating margin
-7.3%
Net margin
-6.9%
EPS (TTM, diluted)
$-1.29

Growth

Revenue growth
−20.4%
Change in growth rate
−18.2 pts
Share count change
−3.1%

Cash

Free cash flow (TTM)
$81.8M
FCF margin
4.1%
Stock pay % of revenue
5.0%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Sarepta Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Sarepta Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$22 ~$14–$27 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$30 ~$29–$58 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$28 ~$28–$35 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sarepta Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$38.58$27.43$55.64$109.13$129.04$170.49$90.05$129.58$96.43$121.59$21.52$18.32
Market value$1.6bn$1.3bn$3.3bn$7.2bn$9.5bn$13.3bn$7.3bn$11.3bn$8.9bn$13.1bn$2.2bn$1.9bn
+ Net debt (− = net cash)−$51m−$105m−$169m$50m−$835m−$1.5bn−$1.6bn$578m$810m$34m$28m$276m
Enterprise value$1.6bn$1.2bn$3.1bn$7.3bn$8.7bn$11.8bn$5.8bn$11.9bn$9.7bn$13.2bn$2.2bn$2.2bn
Multiples
Price / sales n/mn/m21.2x24.0x24.9x24.6x10.4x12.2x7.2x6.9x1.0x1.0x
Price / earnings —————————55.8x——
Price / free cash flow —————n/m—————23.7x
EV / EBITDA —————————51.4x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

10 /100

Weak moat

How hard Sarepta Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -17.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -52.5%; its worst year was -162.9%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 9 years, at a median -41.6% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 39.8% over five years; stock-based pay has been a median 17.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $350m and EPS of $0.36 (range −$0.06 to $1.06) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $4.32 +186% $1.8bn −17%
Next $2.45 −43% $1.4bn −25%

Next year's EPS estimate has moved 0.0% in 90 days, across 10 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.49 $0.64 +31.7%
Mar 2026 $1.05 $3.16 +202.1%
Dec 2025 −$0.77 −$3.58 −365.3%
Sept 2025 −$0.37 −$0.13 +65.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

24 analysts, Oct 2026
Buy729%
Hold1250%
Sell521%

Monthly trend

  1. Oct 20267123224
  2. Sep 20267123224
  3. Aug 20268113224
  4. Jul 20268113224

Counts of recommendations published by analysts covering Sarepta Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
25.9%
of tradable shares
Days to cover
7.77
at average volume
Short interest, 1 month
−7%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
4.9%
of shares
Employees
835
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −23.7%

$24.01 on October 31, 2025 to $18.32

ThenNowEffect
Revenue (last 12 months) $2.5bn $2.0bn −20.4%
P/S multiple 1.1x 1.0x −7.0%
Share count 109m 106m +3.2%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −76.5%

$78.01 on November 3, 2023 to $18.32

ThenNowEffect
Revenue (last 12 months) $1.0bn $2.0bn +96.8%
P/S multiple 6.8x 1.0x −85.6%
Share count 88m 106m −16.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SRPT−47%+44%−26%+26%−82%−15%
Industry peers (median)−35%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SRPT50%83%50%58%33%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SRPT−61%−31%−57%−36%−91%−38%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 93% from December 22, 2020 to July 25, 2025. Getting back needed a 1398% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$14.86 – $24.45
From 52-week high
−25.1%
vs 50-day average
−4.7%
vs 200-day average
−2.1%
Volatility (1 year)
79%
Beta vs S&P 500
2.06

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±10.3%
After a week
4 up, 8 down
typical move ±13.7%
After a month
5 up, 7 down
typical move ±17.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +2.4% −0.4% +12.1% +40.3%
May 6, 2026 −4.5% +1.1% −13.5% −27.7%
February 25, 2026 −7.4% +0.3% −14.6% +15.1%
January 12, 2026 −9.9% 0.0% −11.7% −24.6%
November 3, 2025 −32.5% −1.0% −28.1% −9.0%
July 16, 2025 +20.6% +0.9% −26.9% +11.5%
February 26, 2025 −3.6% −1.5% +0.7% −32.9%
January 13, 2025 −4.8% +0.3% −6.4% −12.0%
January 8, 2024 +23.0% +1.3% +18.5% +29.5%
January 9, 2023 −2.6% +0.6% +6.3% −0.7%
January 10, 2022 −10.7% +0.8% −22.7% −7.7%
October 15, 2021 −2.1% +1.1% −3.3% +1.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Sarepta Therapeutics, Inc.
$1B $1.5B $2B $2.5B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.1B Revenue (TTM), FY23 Q4: $1.2B Revenue (TTM), FY24 Q1: $1.4B Revenue (TTM), FY24 Q2: $1.5B Revenue (TTM), FY24 Q3: $1.6B Revenue (TTM), FY24 Q4: $1.9B Revenue (TTM), FY25 Q1: $2.2B Revenue (TTM), FY25 Q2: $2.5B Revenue (TTM), FY25 Q3: $2.4B Revenue (TTM), FY25 Q4: $2.2B Revenue (TTM), FY26 Q1: $2.2B Revenue (TTM), FY26 Q2: $2B $2B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.1B
FY23 Q4 $1.2B
FY24 Q1 $1.4B
FY24 Q2 $1.5B
FY24 Q3 $1.6B
FY24 Q4 $1.9B
FY25 Q1 $2.2B
FY25 Q2 $2.5B
FY25 Q3 $2.4B
FY25 Q4 $2.2B
FY26 Q1 $2.2B
FY26 Q2 $2B
Revenue growth, TTM YoY Sarepta Therapeutics, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 26.1% Revenue growth, TTM YoY, FY23 Q4: 33.3% Revenue growth, TTM YoY, FY24 Q1: 43.8% Revenue growth, TTM YoY, FY24 Q2: 50.0% Revenue growth, TTM YoY, FY24 Q3: 48.5% Revenue growth, TTM YoY, FY24 Q4: 53.0% Revenue growth, TTM YoY, FY25 Q1: 59.2% Revenue growth, TTM YoY, FY25 Q2: 64.9% Revenue growth, TTM YoY, FY25 Q3: 47.1% Revenue growth, TTM YoY, FY25 Q4: 15.6% Revenue growth, TTM YoY, FY26 Q1: -2.2% Revenue growth, TTM YoY, FY26 Q2: -20.4% -20.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 26.1%
FY23 Q4 33.3%
FY24 Q1 43.8%
FY24 Q2 50.0%
FY24 Q3 48.5%
FY24 Q4 53.0%
FY25 Q1 59.2%
FY25 Q2 64.9%
FY25 Q3 47.1%
FY25 Q4 15.6%
FY26 Q1 -2.2%
FY26 Q2 -20.4%
Operating margin (TTM) Sarepta Therapeutics, Inc.
-40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -36.1% Operating margin (TTM), FY23 Q4: -21.5% Operating margin (TTM), FY24 Q1: -6.8% Operating margin (TTM), FY24 Q2: 2.5% Operating margin (TTM), FY24 Q3: 4.9% Operating margin (TTM), FY24 Q4: 11.5% Operating margin (TTM), FY25 Q1: -5.2% Operating margin (TTM), FY25 Q2: -0.0% Operating margin (TTM), FY25 Q3: -5.2% Operating margin (TTM), FY25 Q4: -31.8% Operating margin (TTM), FY26 Q1: -1.9% Operating margin (TTM), FY26 Q2: -7.3% -7.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -36.1%
FY23 Q4 -21.5%
FY24 Q1 -6.8%
FY24 Q2 2.5%
FY24 Q3 4.9%
FY24 Q4 11.5%
FY25 Q1 -5.2%
FY25 Q2 -0.0%
FY25 Q3 -5.2%
FY25 Q4 -31.8%
FY26 Q1 -1.9%
FY26 Q2 -7.3%
FCF margin (TTM) Sarepta Therapeutics, Inc.
-60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -54.6% FCF margin (TTM), FY23 Q4: -46.4% FCF margin (TTM), FY24 Q1: -45.1% FCF margin (TTM), FY24 Q2: -33.7% FCF margin (TTM), FY24 Q3: -28.7% FCF margin (TTM), FY24 Q4: -18.0% FCF margin (TTM), FY25 Q1: -31.1% FCF margin (TTM), FY25 Q2: -18.2% FCF margin (TTM), FY25 Q3: -15.8% FCF margin (TTM), FY25 Q4: -14.0% FCF margin (TTM), FY26 Q1: 5.3% FCF margin (TTM), FY26 Q2: 4.1% 4.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -54.6%
FY23 Q4 -46.4%
FY24 Q1 -45.1%
FY24 Q2 -33.7%
FY24 Q3 -28.7%
FY24 Q4 -18.0%
FY25 Q1 -31.1%
FY25 Q2 -18.2%
FY25 Q3 -15.8%
FY25 Q4 -14.0%
FY26 Q1 5.3%
FY26 Q2 4.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 10 1 5 155 301 381 540 702 933 1,243 1,902 2,198 1,974
Gross profit — — — — — — — — — — — 2,173 —
EBITDA −130 −215 −261 −164 −331 −681 −537 −422 −494 −223 256 −655 −99
Operating income −134 −220 −267 −172 −344 −706 −564 −460 −536 −268 218 −700 −143
Net income −136 −220 −267 −51 −362 −715 −554 −419 −703 −536 235 −713 −137
Diluted EPS −$3.39 −$5.20 −$5.49 −$0.86 −$5.46 −$9.71 −$7.11 −$5.15 −$8.03 −$5.80 $2.34 −$7.13 −$1.29
Growth (year on year)
Revenue — −87.2% +332.6% +>999% +94.7% +26.5% +41.8% +30.0% +32.9% +33.3% +53.0% +15.6% −20.4%
EBITDA — — — — — — — — — — — −356.2% —
Operating income — — — — — — — — — — — −420.9% —
Net income — — — — — — — — — — — −403.3% —
Diluted EPS — — — — — — — — — — — −404.7% —
Margins
Gross margin — — — — — — — — — — — 98.8% —
EBITDA margin <−999% <−999% <−999% −105.8% −110.1% −178.8% −99.5% −60.1% −53.0% −18.0% 13.4% −29.8% −5.0%
Operating margin <−999% <−999% <−999% −111.0% −114.1% −185.3% −104.5% −65.5% −57.5% −21.5% 11.5% −31.8% −7.3%
Net margin <−999% <−999% <−999% −32.8% −120.2% −187.8% −102.6% −59.7% −75.4% −43.1% 12.4% −32.5% −6.9%
Free-cash-flow margin <−999% <−999% <−999% −157.8% −149.4% −135.5% 4.7% −68.6% −38.2% −46.4% −18.0% −14.0% 4.1%
Cash flow
Cash from operations −129 −149 −246 −232 −389 −456 107 −443 −325 −501 −206 −205 111
Capital spending 25 3 5 12 61 60 82 38 31 76 137 102 29
Free cash flow −154 −153 −251 −244 −450 −516 25 −482 −356 −577 −343 −307 82
Stock-based pay 20 32 30 30 50 79 108 114 233 183 184 123 99
Free cash flow after stock pay −174 −185 −281 −274 −500 −595 −83 −596 −589 −760 −527 −431 −17
Balance sheet
Cash 74 80 122 600 371 835 1,503 2,116 967 428 1,103 801 571
Total debt 10 29 18 431 421 — 0 564 1,544 1,238 1,137 829 848
Net debt (negative = net cash) −64 −51 −105 −169 50 −835 −1,503 −1,552 578 810 34 28 276
Diluted shares 40m 42m 49m 59m 66m 74m 78m 81m 88m 92m 108m 100m 106m
Returned to shareholders
Buybacks — — — — — — — — — 0 0 25 —
Total returned — — — — — — — — — 0 0 25 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $3.2bn
Short-term assets $2.2bnLonger-term assets $965m
What it owes, and who funded it · $3.2bn
Short-term liabilities $503mLonger-term liabilities $1.2bnShareholders' equity $1.5bn
  • Short-term assets cover short-term liabilities $2.2bn of assets due within a year against $503m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.2bn short-term assets against $1.2bn of longer-dated liabilities.
  • More cash than debt $571m of cash against $848m of debt.
  • Debt below 40% of shareholders' equity Debt is 55% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 61% to 55% over five years.
  • A year's operating cash flow covers at least 20% of debt $111m of operating cash flow against $848m of debt.
  • Operating profit covers interest at least five times over Operating income of −$143m against −$81m of interest.

From Sarepta Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$25M
Diluted share count
−3.1%
year over year
R&D spending
40.0%
of revenue
Sales & admin spending
22.1%
of revenue
Days sales outstanding
70 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated SRPT MRNA ALKS HALO EXEL INSM Median
Revenue, last 12 months $2.0bn $2.2bn $1.7bn $1.7bn $2.5bn $1.5bn $58m
Revenue growth, last 12 months −20.4% −27.6% 10.8% 41.2% 9.1% 240.0% 12.2%
Revenue growth, 3-year average 25.3% −40.6% 4.5% 29.1% 12.1% 75.6% 14.3%
Revenue growth, latest quarter −34.3% 2.1% 27.0% 47.7% 10.2% 268.4% 10.2%
Gross margin 46.6% 23.4% 84.6% 82.4% 96.3% 84.4% 82.8%
Operating margin −7.3% −149.0% 7.0% 35.9% 40.2% −37.1% −187.2%
Operating margin, 3-year average −1.6% −115.7% 17.2% 46.6% 33.4% −179.0% −361.6%
Net margin −6.9% −141.4% 4.0% 24.9% 35.5% −39.9% −163.5%
Cash from operations / revenue 5.6% −48.2% 15.1% 49.2% 47.0% −39.2% −162.3%
Free-cash-flow margin 4.1% −55.8% 13.3% 48.5% 46.5% −41.3% −156.7%
Free-cash-flow margin, 3-year average −15.9% −82.7% 22.3% 47.0% 33.8% −143.2% −306.5%
Stock pay / revenue 5.0% 20.7% 7.1% 3.8% 4.4% 11.0% 19.2%
Change in share count −3.1% 2.0% 1.1% −4.2% −7.5% 13.7% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Pmo Products $966M ▼ 0.2%
Elevidys $899M ▲ 9.5%

These categories overlap or exclude eliminations, so shares aren't shown.

From Sarepta Therapeutics, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.9B
Institutions reporting
322
Shares held vs prior quarter
▲ 4.9%
Positions opened / closed
44 / 65

Top buyers and sellers, Q2 2026: 142 institutions bought and 183 sold ; the biggest buyer was Blackrock, Inc (+4.2M shares) and the biggest seller RA Capital Management, L.P (−3.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $341M 19.0M 17.6% ▲ 28.7%
State Street Corp $160M 8.9M 8.3% ▲ 34.8%
Vanguard Portfolio Management LLC $151M 8.4M 7.8% ▲ 26.2%
Two Sigma Investments, LP $82.6M 4.6M 4.3% ▲ 0.1%
Vanguard Capital Management LLC $82.5M 4.6M 4.3% ▲ 0.3%
First Trust Advisors LP $78.5M 4.4M 4.0% ▲ 5.6%
AQR Capital Management LLC $76.9M 4.3M 4.0% ▼ 32.8%
Geode Capital Management, LLC $49.8M 2.8M 2.6% ▲ 39.4%
Erste Asset Management Gmbh $45.5M 2.6M 2.3% ▼ 13.5%
Marshall Wace, LLP $39.6M 2.2M 2.0% ▲ 204.3%
Morgan Stanley $39.6M 2.2M 2.0% ▼ 15.2%
Aberdeen Group PLC $39.4M 2.2M 2.0% ▼ 5.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sarepta Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $417,410 2 trades by 2 insiders · 0% under pre-set plans
Net ▼ $417,410 net selling
Insider Date Trade Shares Price Value
Mayo Stephen Director March 12, 2026 Sell 7,239 $17.02 $123,208
Estepan Ian Michael Chief Operating Officer December 16, 2025 Sell 13,187 $22.31 $294,202

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 17 trades and filings

No trades in Sarepta Therapeutics, Inc. disclosed in the last 12 months; 17 earlier trades on record.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (full), $1,001 - $15,000, traded April 14, 2025, filed May 6, 2025
  • Josh Gottheimer(D-NJ 5):Purchase, $1,001 - $15,000, traded July 14, 2023, filed August 21, 2023
  • Josh Gottheimer(D-NJ 5):Sale (full), $1,001 - $15,000, traded June 13, 2023, filed July 11, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 25, 2026
  • January 12, 2026
  • November 3, 2025
  • July 16, 2025

Recent SEC filings

Data status

When each part of this page on Sarepta Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sarepta Therapeutics, Inc. in brief

What does Sarepta Therapeutics, Inc. do?
Sarepta Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Sarepta Therapeutics, Inc.'s stock ticker?
Sarepta Therapeutics, Inc. trades under the ticker SRPT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Sarepta Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Sarepta Therapeutics, Inc. reported revenue of $2B, 20.4% lower than a year earlier, according to its SEC filings.
What is Sarepta Therapeutics, Inc.'s free cash flow?
Sarepta Therapeutics, Inc.'s free-cash-flow margin is 4.1% of revenue over the trailing twelve months.
Who are Sarepta Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., State Street Corp and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Sarepta Therapeutics, Inc.'s market cap?
On November 2, 2026, Sarepta Therapeutics, Inc.'s market capitalisation was about $1.9B and net debt of $276M. Market figures come from third-party market data and may be delayed.
How much debt does Sarepta Therapeutics, Inc. have?
Sarepta Therapeutics, Inc.'s debt-to-equity ratio is 55.5%, from its latest balance sheet (60.7% five years earlier). The financial health section below sets out its other solvency checks.
Who are Sarepta Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Sarepta Therapeutics, Inc. are Moderna, Alkermes plc., Halozyme Therapeutics, Inc., Exelixis, Inc. and Insmed Inc. The side-by-side comparison below sets their revenue, margins and growth against Sarepta Therapeutics, Inc.'s.
Are insiders buying or selling Sarepta Therapeutics, Inc. stock?
Over the last 12 months, Sarepta Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Sarepta Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Sarepta Therapeutics, Inc. announces its own schedule.